Feasibility study testing the protocol of single dose of psilocybin given to people who have had little improvements with brief psychological intervention
This open-label trial (n=30) will study the feasibility of administering a single dose of psilocybin (25mg) to adults with mild to moderate depression or anxiety who have shown limited improvement with brief psychological intervention.
Details
Open-label, non-randomised, single-group feasibility study (n=30) administering a single morning oral dose of psilocybin 25 mg with 8 hours monitoring to adults with moderate depression or anxiety who had limited benefit from brief psychological interventions.
Screening includes one two-hour session; acute measures at ~4 hours, subacute at 24 hours, and outcomes at 6 and 12 weeks. Primary outcomes include recruitment and retention at dosing and follow-up and composite depression/anxiety scores (DASS-21, BAI, BDI-2).